t is December 2022. You work as a financial analyst for Merck & Co. and are tasked with the due diligence on the proposed acquisition of a biotech startup. You estimated the following cash flows for the startup:

Year	Expected free cash flow ($ million) (end of year)
2023	89.5
2024	134.25
2025	174.53
2026	209.43
2027	230.37

After 2027, cash flows are expected to grow by 4% per year. Based on the riskiness of your industry, you think that your weighted average cost of capital is 18%.

The biotech firm has 5 million shares and bonds worth $120 million outstanding.

Attempt 4/10 for 10 pts.

Part 1

What is the terminal value, i.e., the present value of all free cash flows from 2028 to infinity expressed in 2027-dollars (in $ million)?

Submit

Attempt 1/10 for 10 pts.

Part 2

What is the total value of the company (in $ million)?

Submit

Attempt 1/10 for 10 pts.

Part 3

What is the value per share of common stock (in $)?